Prevalence of metabolic syndrome in young patients with ST-elevation myocardial infarction

Öz, Tuğba Kemaloğlu; Özbilgin, Nazmiye; Sungur, Aylin; Bas, Elif Gulsah; Zengin, Ahmet; Gürol, Tayfun; Soylu, Özer; Dağdeviren, Bahadır

doi:10.4103/ijca.ijca_10_18

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these studies were consistent with the evidence that increased HDL-C plasma levels are associated with a reduced risk of CVD and MI, due to different mechanisms such as reverse cholesterol transportation and inhibition of in ammatory factor expression accomplished by this lipoprotein (49,50). Additionally, we observed a positive association between high HDL-C levels and ST-segment elevation as a minor ischemic abnormality, which was contrary with previous studies that had announced low HDL-C as a risk factor for ST-elevation myocardial infarction (STEMI) (51,52). In a study conducted by Kumar et al, on 3224 participants with the mean age of 72, no signi cant association was observed between HDL-C and NSSTTAs in older Americans (42); also, in a heterogeneous population-based study from the U.S., there was no signi cant relationship between low HDL-C and ECG abnormalities (34); in addition, a Korean study declared that low HDL-C was not a signi cant risk factor for ischemic ECG presentations in female (32).…”

Section: Discussioncontrasting

confidence: 99%

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Soflaei,

Varasteh,

Pourali

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Metabolic syndrome (MetS) is a set of metabolic impairments that are all risk factors for cardiovascular diseases (CVDs). To distinguish and anticipate the CVD risk, an electrocardiogram (ECG) can be utilized. While the exact association between MetS components and ECG abnormalities isn’t well established yet, we designed this study to verify the association between MetS components and ischemic ECG presentations. Methods This cross-sectional study was conducted on individuals aged 35–65 years as part of the population-based Mashhad stroke and heart atherosclerotic disorder (MASHAD) study. International Diabetes Federation (IDF) criteria were utilized to categorize the participants into two groups: those with and without MetS. ECGs were coded using the Minnesota coding system. The association between each MetS component and every single ischemic ECG presentation was analysed separately. Results Among the 9035 available ECG data, the general prevalence of ischemic ECG presentation was significantly higher in those with MetS than in those without (p < 0.05), except for minor ischemia (P = 0.787). Multiple logistic regression analysis showed that MetS was independently associated with major ischemia presentation in ECG (OR = 1.254, 95% Cl: 1.103–1.425, P < 0.001), but there wasn’t any association found with minor ischemia, after adjustment for age, sex, smoking, CVD family history, and physical activity level. Among Mets components, triglycerides, fasting blood glucose, waist circumference, and systolic and diastolic blood pressures had significantly positive associations with ischemic ECG presentations in the case of any association. Elevated high-density lipoprotein cholesterol level had negative associations with ischemic ECG presentations, while it had a significant positive association only with ST-segment elevation (OR = 1.021, 95% Cl: 1.011–1.031, P < 0.001). Conclusions MetS and its components showed an association with ischemic ECG presentations, but these associations were diverse, based on each MetS component and ischemic ECG abnormality.

show abstract

Section: Discussioncontrasting

confidence: 99%

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Soflaei,

Varasteh,

Pourali

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…6 Significant stenosis of LM, in most studies, is more common in patients with MS when compared to those without it (13.1% vs 4.45%). 1 This was in correlation with our re- stenoza LAD u svim studijama najveća, kao i u grupi naših ispitanika 13,34 .…”

Section: Discussionsupporting

confidence: 61%

Influence of metabolic syndrome on coronary arteries features in people with myocardial infarction

Miljković¹

2020

Opšta medicina

View full text Add to dashboard Cite

Uvod. Prethodna epidemiološka i klinička ispitivanja potvrdila su povezanost između metaboličkog sindroma i povećanog rizika za nastanak koronarne bolesti. Pokazana je značajna povezanost ovog sindroma sa angiografski težim lezijama koronarnih arterija. Cilj rada. Cilj rada je bio da ispitamo značaj i uticaj metaboličkog sindroma na težinu angiografskih promena koronarnih arterija kod bolesnika sa infarktom miokarda. Metod. Ispitivanjem su obuhvaćena 143 bolesnika sa infarktom miokarda, 81 (58,7±6,2) sa i 62 (54,9±10,3) bez metaboličkog sindroma (p<0,01). Kod svih ispitanika urađeni su klinički pregledi, antropometrijska merenja, laboratorijska i koronarografska dijagnostika. Za postavljanje dijagnoze metaboličkog sindroma korišćeni su kriterijumi Američkog udruženja za srce i Nacionalnog instituta za srce, pluća i krv. Rezultati. Osobe sa metabolićkim sindromom, u poređenju sa onima bez MS, imaju: jednosudovnu 8,6% vs 46,8% (p<0,001), dvosudovnu 25,9% vs 32,3% (p>0,05), trosudovnu 65,4% vs 21,0% (p<0,001), višesudovnu bolest 91,3% vs 53,2% (p<0,001). Od pojedinačnih koronarnih arterija, značajne stenoze nađene su kod ispitanika sa MS, u poređenju sa ispitanicima bez MS: LAD 88,9% vs 71,0% (p<0,01), LCX 64,2% vs 29,0% (p<0,01), RCA 80,2% vs 61,3% (p<0,01), LM 14,8% vs 1,6%. Zaključak. Pacijenti sa MS imaju teže angiografske promene na koronarnim arterijama sa većom učestalošću trosudovne i višesudovne bolesti i stenoza LAD, LCX, RCA, LM, u poređenju sa onima bez MS, što pokazuje da je MS značajan faktor rizika za nastanak i razvoj teže koronarne bolesti.

show abstract

“…In a comprehensive study in six Middle Eastern countries (Bahrain, Kuwait, Qatar, Oman, Yemen, and the United Arab Emirates) in 2010 on hospitalized patients with the acute coronary syndrome, the overall prevalence of the syndrome was 46% [21]. In Oz et al's study, the prevalence of MetS in young Turkish patients with STEMI was about 46%, but this study was limited to patients younger than 46 years old [22].…”

Section: Discussionmentioning

confidence: 94%

Impact of Metabolic Syndrome in Patients With Acute Myocardial Infarction After Thrombolytic Therapy

Sobhani

Daei²,

Dodangeh³

et al. 2022

J Inflamm Dis

View full text Add to dashboard Cite

Background: Metabolic syndrome (MetS) comprises a group of conditions that happen together and increase the risk of heart disorders. MetS has known characteristic diagnostic criteria and is diagnosed through physical examination and blood tests. This syndrome is extremely prevalent in patients with acute myocardial infarction. We aimed to determine the prevalence of MetS and its relationship with myocardial infarction and response to treatment in patients suffering from acute myocardial infarction under fibrinolytic treatment. Methods: In this cross-sectional study, 145 patients with acute ST-elevation myocardial infarction (STEMI) were enrolled. They were referred to Bu-Ali Sina Hospital in Qazvin, Iran, between January 2018 and January 2019 and were candidates for thrombolytic therapy. The patients were divided into two groups with and without MetS according to the NCEP ATP III definition (the National Cholesterol Education Program-Adult Treatment Panel III). In each group, the ST resolution of more than 50% in electrocardiogram was evaluated 90 minutes after thrombolytic administration. In addition, angiographic information and left ventricular ejection fraction (LVEF) were compared between the two groups. Results: Overall, the prevalence of MetS was 57.2% in the study population. After treatment, ST-segment resolution of more than 50%, the number of involved coronary vessels, the thrombolysis in myocardial infarction flow grade, mean LVEF, and type of myocardial infarction were similar in both study groups. Conclusion: Our study indicates that MetS does not affect the response rate to thrombolytic treatment.

show abstract

Prevalence of metabolic syndrome in young patients with ST-elevation myocardial infarction

Cited by 6 publications

References 0 publications

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Influence of metabolic syndrome on coronary arteries features in people with myocardial infarction

Impact of Metabolic Syndrome in Patients With Acute Myocardial Infarction After Thrombolytic Therapy

Contact Info

Product

Resources

About